Hung cites Shin Kong as an example: The hospital group generates nearly NT $ 200 million in revenues from cancer screenings, NT $ 70-80 million of that from run-of-the-mill colonoscopies, mammograms, and tumor-marker testing, and more than NT $ 100 million of the remainder from positron emission tomography (PET) scans.
洪子仁舉新光為例：一年逼近兩億台幣的癌檢收入，其中 7 至 8 千萬元來自包含大腸鏡、女性乳房攝影、腫瘤標記檢測等「一般健檢」，另外一筆超過一億元的營業額，則是出自民眾額外加做的「正子斷層造影」檢查（簡稱「正子掃描」）。